In stock
VELCADE 3.5MG POWDER FOR I.V. INJECTION 3.5 mg powder for solution for injection 10ml Vial
In stock
Only 1 left
SKU
10331014162
VELCADE 3.5mg Powder for Solution for Injection contains Bortezomib, a proteasome inhibitor used to treat multiple myeloma and mantle cell lymphoma. It is administered intravenously and works by inducing programmed cell death in cancer cells. This prescription medication requires professional reconstitution and administration.
Explore VELCADE 3.5mg Powder for Solution for Injection, a vital medication available on leading e-commerce platforms like Nahdi Online, , and , offering comprehensive information and accessibility for healthcare professionals and patients.
VELCADE 3.5mg Powder for Solution for Injection is a potent antineoplastic agent designed for intravenous administration.
This specialized medication, containing Bortezomib, is critical in treating certain types of cancer by targeting specific cellular processes.
It comes as a lyophilized powder in a 10ml vial, requiring reconstitution before use.
Velcade has been a cornerstone in various treatment regimens, reflecting its importance in modern oncology practices.
This product contains 3.5 mg of Bortezomib per vial.
It is formulated as a powder for solution for injection.
The vial capacity is 10ml, allowing for proper reconstitution with the recommended diluent.
VELCADE is manufactured by Takeda Pharmaceutical Company, a leader in innovative medicines.
Velcade (Bortezomib) is a proteasome inhibitor that plays a crucial role in treating specific hematologic malignancies.
It is primarily indicated for the treatment of multiple myeloma and mantle cell lymphoma.
Bortezomib works by reversibly inhibiting the 26S proteasome, a multiprotein complex that degrades ubiquitinated proteins.
This inhibition disrupts cellular processes, leading to apoptosis (programmed cell death) in cancer cells.
It can significantly improve response rates and progression-free survival in eligible patients.
1. VELCADE 3.5mg powder must be reconstituted by a healthcare professional.
2. Reconstitute the 3.5 mg vial with 3.5 mL of 0.9% Sodium Chloride Injection.
3. This results in a final concentration of 1 mg/mL for intravenous administration.
4. Administer the reconstituted solution as an intravenous bolus injection over 3-5 seconds.
5. The specific dosage and treatment schedule will be determined by your physician based on your condition and response to therapy.
Active Ingredient: Bortezomib (3.5 mg per vial)
Excipients: Mannitol, Hydrochloric acid (for pH adjustment) and/or Sodium Hydroxide (for pH adjustment).
Product Overview
VELCADE 3.5mg Powder for Solution for Injection is a potent antineoplastic agent designed for intravenous administration.
This specialized medication, containing Bortezomib, is critical in treating certain types of cancer by targeting specific cellular processes.
It comes as a lyophilized powder in a 10ml vial, requiring reconstitution before use.
Velcade has been a cornerstone in various treatment regimens, reflecting its importance in modern oncology practices.
Product Details
This product contains 3.5 mg of Bortezomib per vial.
It is formulated as a powder for solution for injection.
The vial capacity is 10ml, allowing for proper reconstitution with the recommended diluent.
VELCADE is manufactured by Takeda Pharmaceutical Company, a leader in innovative medicines.
Benefits of Use
Velcade (Bortezomib) is a proteasome inhibitor that plays a crucial role in treating specific hematologic malignancies.
It is primarily indicated for the treatment of multiple myeloma and mantle cell lymphoma.
Bortezomib works by reversibly inhibiting the 26S proteasome, a multiprotein complex that degrades ubiquitinated proteins.
This inhibition disrupts cellular processes, leading to apoptosis (programmed cell death) in cancer cells.
It can significantly improve response rates and progression-free survival in eligible patients.
How to Use
1. VELCADE 3.5mg powder must be reconstituted by a healthcare professional.
2. Reconstitute the 3.5 mg vial with 3.5 mL of 0.9% Sodium Chloride Injection.
3. This results in a final concentration of 1 mg/mL for intravenous administration.
4. Administer the reconstituted solution as an intravenous bolus injection over 3-5 seconds.
5. The specific dosage and treatment schedule will be determined by your physician based on your condition and response to therapy.
Caution & Warnings
- Administer VELCADE only under the supervision of a physician experienced in the use of antineoplastic therapy.
- Peripheral neuropathy, including severe forms, is a common and potentially dose-limiting adverse reaction.
- Thrombocytopenia, neutropenia, and anemia are common and require regular monitoring of blood counts.
- Orthostatic hypotension can occur; patients should be advised to change positions slowly.
- Congestive heart failure, acute renal failure, and posterior reversible encephalopathy syndrome (PRES) have been reported.
- Patients should be monitored for signs and symptoms of these conditions.
- This medication is for intravenous use only and should not be administered by any other route.
- Do not use if the solution is discolored or contains particulate matter after reconstitution.
- Keep out of reach of children.
Ingredients
Active Ingredient: Bortezomib (3.5 mg per vial)
Excipients: Mannitol, Hydrochloric acid (for pH adjustment) and/or Sodium Hydroxide (for pH adjustment).
| Gtin | 89-6-06 |
|---|---|
| Recommended Sale Price | 3960.05 |
| Is Wasfaty Product | No |
| Brand | Not Defined |
| Ingredient Name | BORTEZOMIB |
| SFDA Reg. No | 89-6-06 |
| IBC | 89-6-06 |
| Drug Type | Prescription |
| Scientific Name | Bortezomib |
| Strength | 3.5 mg |
| Strength Unit | mg |
| Form | Powder for solution for injection |
| Admin Route | Intravenous |
| Size | 10 ml |
| Size Unit | ml |
| Package Types | Vial |
| Package Size | 1 vial |
| shelfLife | 24 months |
| Storage conditions | Store at 25°C, excursions permitted to 15-30°C. Protect from light. |
| Refrigerator Storage | No |
Products you might like
